Celine Halioua is the founder and CEO of Loyal, a biotechnology company developing drugs intended to extend dog lifespan. Her work focuses on biotechnology, pathological aging, healthcare systems, and the economics of preventative and curative medicine.
Celine Halioua is the founder and CEO of Loyal, a biotechnology company developing drugs intended to extend dog lifespan. Her work focuses on biotechnology, pathological aging, healthcare systems, and the economics of preventative and curative medicine.
Career
Celine Halioua studied at University of Texas at Austin (BSc in Neuroscience), Uppsala University (Nanobiotechnology studies), and University of Oxford (D.Phil. studies in health economics of gene therapy; not completed).